Skip to content
   
   
   

4. National TB prevalence surveys, %%YEAR%%

4.1. National TB prevalence estimates

4.1.1 Prevalence of bacteriologically-confirmed pulmonary TB among those aged ≥15 years per 100 000 population

4.1.2 Prevalence of bacteriologically-confirmed pulmonary TB who are smear-positive among those aged ≥15 years per 100 000 population

4.1.3 Prevalence of bacteriologically-confirmed pulmonary TB per 100 000 population by age group (years)

4.1.4 Prevalence of bacteriologically-confirmed pulmonary TB who are smear positive per 100 000 population by age group (years)

4.1.5 Rate ratio of prevalent to notified TB cases by sex

4.1.6 Rate ratio of prevalent to notified TB cases by age group

4.2. Survey flow: census to final outcome

PSFlow

4.3. Screening and diagnosis

4.3.1 Percentage of survey participants with radiological abnormalities (screen positive) from the field reading

4.3.2 Percentage of survey participants with symptoms suggestive of pulmonary TB

4.3.3 Percentage of people diagnosed with bacteriologically confirmed TB during the survey who did not report screening symptoms

4.3.4 Percentage of people diagnosed with bacteriologically confirmed TB during the survey who were currently on TB treatment

4.4. Health-care seeking behaviour

4.4.1 Percentage of symptom-screen positive survey participants who did not seek care

4.4.2 Percentage of symptom-screen positive survey participants who sought care by health facility type

4.4.3 Percentage of survey participants currently on TB treatment by health facility type

Metadata

Glossary and definitions

Bacteriologically confirmed

A person from whom a bacteriological specimen is positive by a WHO recommended rapid diagnostic test, culture, or smear microscopy.

Pulmonary TB

A person with TB disease involving the lung parenchyma or the tracheobronchial tree.

Prevalence to notification ratio

TB prevalence measured in the survey divided by the notification rate for bacteriologically confirmed TB among those aged ≥15 years in the main year of the survey.

Screening symptom

The main screening criterion for the prevalence survey is a chronic cough (i.e. ≥2 weeks in most surveys).  However, screening criteria might vary by country, by broadening criteria, including combination of cough of any duration, loss of body weight, shortness of breath, loss of appetite, weight loss, fever, haemoptysis, chest pain, night sweats, fever and history of TB.

Radiological abnormality

Any lung (including pleura) abnormality detected on interpretation by the medical officer (e.g. opacities, cavitation, fibrosis, pleural effusion, calcification(s), any unexplained or suspicious shadow, etc). Congenital abnormalities, normal variants, any bony abnormalities like fractures are excluded by definitions as are findings like increased heart size, and other heart-related abnormalities. 

Percentage of symptom-screen positive participants who sought care by health facility type

Percentage of symptom-screen positive survey participants, reporting having sought medical advice by the type of facility among all participants who sought care. 

Percentage of survey participants with symptoms suggested for pulmonary TBPercentage of survey participants with TB with symptoms suggestive of pulmonary TB according to NTP definitions.  Symptoms suggestive for TB may vary by survey. The main symptom screening criterion is a chronic cough (i.e. ≥2 weeks in most surveys). Other symptoms might include chest pain, night sweats, shortness of breath, loss of appetite, weight loss, fever or haemoptysis or combination of symptoms.
Percentage of bacteriologically confirmed TB currently on treatment

Percentage of prevalent TB cases (according to survey definitions) who are on TB treatment.

Percentage of survey participants who were currently on TB treatment by health facility type

Percentage of survey participants who were currently on TB treatment by health facility type, including public, private, other and unknown health facility.

Percentage of symptom-screen positive participants who did not seek care

Percentage of symptom-screen positive survey participants eligible for sputum examination, reporting having not sought medical advice. 

Copyright and licensing

Copyright

Attribution 4.0 International (CC BY 4.0)

License

The World Health Organization (“WHO”) encourages public access and use of the data that it collects and publishes on its web site data.who.int. The data are organized in datasets and made available in machine-readable format (“Datasets”). The Datasets have been compiled from data provided by WHO’s Member States under the WHO policy on the use and sharing of data collected by WHO in Member States outside the context of public health emergencies.

Use of the data derived from the Datasets, which may appear in formats such as tables and charts, is also subject to these Terms and Conditions. Datasets may include data describing the Dataset called “Metadata”. If any datasets are credited to a source other than WHO, then those materials are not covered by these Terms and Conditions, and permission should be sought from the source provided. You are responsible for determining if this is the case, and if so, you are responsible for obtaining any necessary permission from the sources indicated. The risk of claims resulting from infringement of any third-party-owned component in the materials rests solely with you.

You may use our application programming interfaces (“APIs”) to facilitate access to the Datasets, whether through a separate web site or through another type of software application. By using the Datasets or any presentations of data derived from them, or by using our APIs in connection with the Datasets, you agree to be bound by these Terms and Conditions, as may be amended from time to time by WHO at its sole discretion.

Unless specifically indicated otherwise, these Datasets are provided to you under a Creative Commons Attribution 4.0 International License (CC BY 4.0), with the additional terms below. The basic terms applicable to the CC BY 4.0 license may be accessed here. By downloading or using the Datasets, you agree to comply with the terms of the CC BY 4.0 license, as well as the following mandatory and binding addition:

Any dispute relating to the interpretation or application of this license shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the UNCITRAL Arbitration Rules. The parties shall accept the arbitral award as final.

Permission typePublicly accessible
Prohibited uses

You shall not attempt to de-anonymise the Datasets or use the Datasets in a manner that falsifies or misrepresents their content.

You shall not, in connection with your use of the Datasets published on data.who.int, state or imply that WHO endorses, or is affiliated with, you, or that WHO endorses your use of data.who.int, or any content, output, or analysis resulting from or related to the data.who.int, or any entity, organization, company, product or services.

Citation

World Health Organization 2025 data.who.int, WHO TB dashboard [Dashboard]. https://data.who.int/dashboards/tuberculosis/

Disclaimer

WHO reserves the right at any time and from time to time to modify or discontinue, temporarily or permanently, the Datasets, or any means of accessing or utilizing the Datasets with or without prior notice to you.

Maps
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the accuracy of the Datasets. However, the Datasets are being provided without warranty of any kind, either expressed or implied. You will be solely responsible for your use of the Datasets. In no event shall WHO be liable for any damages arising from such use.

For full disclaimers, terms of use and your indemnification of WHO, please visit Terms and Conditions.